{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":45,"n_cols":5,"rows_kept":45,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[11,2,11,3],[12,2,12,3],[15,2,15,3],[24,2,24,3],[24,4,24,5],[25,2,25,3],[25,4,25,5],[26,2,26,3],[28,2,28,3],[29,2,29,3],[30,2,30,3],[31,2,31,3],[32,2,32,3],[33,2,33,3],[34,2,34,3],[36,2,36,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910619286503321"]
[null,null,"Autore",null,"Cavalcanti Iago Dillion Lima"]
[null,null,"Titolo",null,"Chemotherapy protocols and infusion sequence : schedule considerations in cancer treatment / / Iago Dillion Lima Cavalcanti"]
[null,null,"Pubbl/distr/stampa",null,"Cham, Switzerland : , : Springer, , [2022]"]
[{"$nulls":4},"©2022"]
[null,null,"ISBN",null,"9783031108396"]
[{"$nulls":4},"9783031108389"]
[null,null,"Descrizione fisica",null,"1 online resource (330 pages)"]
[null,null,"Disciplina",null,"636.80896994"]
[null,null,"Soggetti",null,"Cancer - Chemotherapy"]
[{"$nulls":4},"Infusion therapy"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Includes index."]
[null,null,"Nota di contenuto",null,"Intro -- Preface -- Contents -- Chapter 1: Polypharmacy in Cancer Therapy -- 1.1 Polypharmacy: Challenges in the Treatment of Chronic Diseases -- 1.2 Scenario of Polypharmacy in Cancer Treatment -- 1.3 Drug Interactions -- 1.3.1 Pharmacodynamic Interactions -- 1.3.2 Pharmacokinetic Interactions -- 1.4 Advantages in Drug Association -- 1.5 Risks of Polypharmacy -- References -- Chapter 2: Combined Therapy for the Treatment of Cancer -- 2.1 Anticancer Therapy -- 2.2 Combination Therapy in Cancer -- 2.2.1 Challenges in Combination Therapy -- 2.3 Toxicity of Combination Therapy for Cancer Treatment -- 2.3.1 Toxicity in the Treatment of Breast Cancer -- 2.3.2 Toxicity in the Treatment of Lung Cancer -- 2.3.3 Toxicity in the Treatment of Colorectal Cancer -- 2.3.4 Toxicity in the Treatment of Prostate Cancer -- 2.3.5 Toxicity in the Treatment of Cervical Cancer -- 2.3.6 Toxicity in the Treatment of Head and Neck Cancer -- 2.3.7 Toxicity in the Treatment of Lymphomas -- References -- Chapter 3: Importance of the Infusion Order in the Treatment of Cancer -- 3.1 Drug Infusion Therapy -- 3.1.1 Types of Infusion According to Administration Time -- 3.2 Dilution of Drugs and Their Stability -- 3.3 Risks of Chemotherapy Infusion -- 3.3.1 Drug Extravasation -- 3.3.1.1 Irritating Antineoplastics -- 3.3.1.2 Vesicant Antineoplastics -- 3.4 Concept and Importance of Infusion Order -- 3.4.1 Factors That May Influence in the Order of Infusion of Antineoplastic Agents -- References -- Chapter 4: Chemotherapeutic Protocols "]
[{"$nulls":4},"for the Treatment of Breast Cancer -- 4.1 Breast Cancer: Epidemiology -- 4.2 Pathophysiology of Breast Cancer -- 4.3 Molecular Subtypes of Breast Cancer -- 4.4 Breast Cancer Treatment Modalities -- 4.5 Adjuvant Chemotherapy -- 4.5.1 AC Protocol (Doxorubicin and Cyclophosphamide)."]
[{"$nulls":4},"4.5.2 ACT, T-AC, or AC-T Protocol (Doxorubicin, Cyclophosphamide, and Paclitaxel) -- 4.5.3 ACTT Protocol (Doxorubicin, Cyclophosphamide, Paclitaxel, and Trastuzumab) -- 4.5.4 CMF Protocol (Cyclophosphamide, Methotrexate, and 5-Fluorouracil) -- 4.5.5 FAC Protocol (5-Fluorouracil, Doxorubicin, and Cyclophosphamide) -- 4.5.6 FEC Protocol (5-Fluorouracil, Epirubicin, and Cyclophosphamide) -- 4.5.7 FEC-D Protocol (5-Fluorouracil, Epirubicin, Cyclophosphamide, and Docetaxel) -- 4.5.8 FEC-DT Protocol (5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel, and Trastuzumab) -- 4.5.9 DAC (Docetaxel, Doxorubicin, and Cyclophosphamide) and DC (Docetaxel and Cyclophosphamide) Protocols -- 4.5.10 TDC Protocol (Trastuzumab, Docetaxel, and Cyclophosphamide) -- 4.5.11 DCARBT Protocol (Docetaxel, Carboplatin, and Trastuzumab) -- 4.6 Chemotherapy in Locally Advanced Breast Cancer -- 4.6.1 AC-DT Protocol (Doxorubicin, Cyclophosphamide, Docetaxel, and Trastuzumab) -- 4.6.2 CT-AC Protocol (Carboplatin, Paclitaxel, Doxorubicin, and Cyclophosphamide) -- 4.7 Chemotherapy in Advanced Breast Cancer -- 4.7.1 GEMD Protocol (Gemcitabine and Docetaxel) -- 4.7.2 GEMP Protocol (Gemcitabine and Cisplatin) -- 4.7.3 GEMT Protocol (Gemcitabine and Paclitaxel) -- 4.7.4 PTRAD Protocol (Pertuzumab, Trastuzumab, and Docetaxel) -- 4.7.5 PTRAT Protocol (Pertuzumab, Trastuzumab, and Paclitaxel) -- 4.7.6 TRVIN Protocol (Trastuzumab and Vinorelbine) -- References -- Chapter 5: Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer -- 5.1 Epidemiological Profile of Cancers of the Gastrointestinal Tract -- 5.2 Pathophysiology of Colorectal Cancer -- 5.2.1 Adjuvant Chemotherapy for the Treatment of Resectable Colorectal Cancer -- 5.2.1.1 CAPOX Protocol (Oxaliplatin and Capecitabine) -- 5.2.1.2 FL Protocol (5-Fluorouracil and Leucovorin)."]
[{"$nulls":4},"5.2.1.3 FOLFOX Protocol (Oxaliplatin, Leucovorin, 5-Fluorouracil, and 5-Fluorouracil in Continuous Infusion) -- 5.2.1.4 RALOX Protocol (Oxaliplatin and Raltitrexed) -- 5.2.2 Chemotherapy for the Treatment of Advanced Unresectable Colorectal Cancer -- 5.2.2.1 CAPB Protocol (Capecitabine and Bevacizumab) -- 5.2.2.2 CETIR Protocol (Cetuximab and Irinotecan) -- 5.2.2.3 FOLFIRI Protocol (Irinotecan, Leucovorin, 5-Fluorouracil, and 5-Fluorouracil in Continuous Infusion) -- 5.2.2.4 CAPIRI Protocol (Capecitabine and Irinotecan) -- 5.2.2.5 CAPIRIB Protocol (Capecitabine, Irinotecan, and Bevacizumab) -- 5.2.2.6 CAPOXB Protocol (Oxaliplatin, Bevacizumab, and Capecitabine) -- 5.2.2.7 FOLFIRIB Protocol (5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, Leucovorin, Irinotecan, and Bevacizumab) -- 5.2.2.8 FOLFIRIPAN Protocol (5-Fluorouracil, Leucovorin, Irinotecan, and Panitumumab) -- 5.2.2.9 FOLFOXB Protocol (Oxaliplatin, Leucovorin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, and Bevacizumab) -- 5.2.2.10 FOLFOXPAN Protocol (Oxaliplatin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, Leucovorin, and Panitumumab) -- 5.3 Pathophysiology of Esophageal and Stomach Cancers -- 5.3.1 Chemotherapy for the Treatment of Esophageal and Stomach Cancer -- 5.3.1.1 FOLFOXT Protocol (Oxaliplatin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, Leucovorin, and Trastuzumab) -- 5.3.1.2 FLOT Protocol (Oxaliplatin, 5-Fluorouracil, Leucovorin, and Docetaxel) -- 5.3.1.3 CTRT Protocol (Carboplatin, Paclitaxel, and Radiotherapy) -- 5.3.1.4 FUC Protocol (5-"]
[{"$nulls":4},"Fluorouracil and Cisplatin) -- 5.3.1.5 CCAPRT Protocol (Cisplatin, Capecitabine, and Radiotherapy) -- 5.3.1.6 CCAPT Protocol (Cisplatin, Capecitabine, and Trastuzumab) -- 5.3.1.7 CFUT Protocol (Cisplatin, 5-Fluorouracil, and Trastuzumab)."]
[{"$nulls":4},"5.3.1.8 CAPOXT Protocol (Capecitabine, Oxaliplatin, and Trastuzumab) -- 5.3.1.9 RAMP Protocol (Paclitaxel and Ramucirumab) -- 5.3.1.10 ECCAP Protocol (Epirubicin, Cisplatin, and Capecitabine) -- 5.4 Pathophysiology of Pancreatic, Biliary Tract, and Gallbladder Cancers -- 5.4.1 Chemotherapy for the Treatment of Pancreatic, Biliary Tract, and Gallbladder Cancers -- 5.4.1.1 GEMCIS Protocol (Gemcitabine and Cisplatin) -- 5.4.1.2 FOLFIRINOX Protocol (Irinotecan, Oxaliplatin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, and Leucovorin) -- 5.4.1.3 GEMCAP Protocol (Capecitabine and Gemcitabine) -- 5.4.1.4 GEMABR Protocol (Gemcitabine and Nab-Paclitaxel) -- 5.5 Pathophysiology of Liver Cancer -- 5.5.1 Chemotherapy for the Treatment of Liver Cancer -- 5.5.1.1 Nivolumab and Ipilimumab Protocol -- 5.5.1.2 Atezolizumab and Bevacizumab Protocol -- 5.6 Pathophysiology of Carcinoid and Neuroendocrine Tumors -- 5.6.1 Chemotherapy for the Treatment of Carcinoid and Neuroendocrine Tumors -- 5.6.1.1 ETCIS Protocol (Etoposide and Cisplatin) -- 5.6.1.2 DS Protocol (Doxorubicin and Streptozotocin) -- 5.7 Pathophysiology of Anal Cancer -- 5.7.1 Chemotherapy in the Treatment of Anal Cancer -- 5.7.1.1 FUMRT Protocol (5-Fluorouracil, Mitomycin C, and Radiotherapy) -- 5.7.1.2 CAPMRT Protocol (Capecitabine, Mitomycin C, and Radiotherapy) -- References -- Chapter 6: Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer -- 6.1 Epidemiological Profile of Genitourinary Cancers -- 6.2 Pathophysiology of Bladder Cancer -- 6.2.1 Chemotherapy for the Treatment of Bladder Cancer -- 6.2.1.1 BCGIFN Protocol (BCG and Interferon) -- 6.2.1.2 GEMDOC Protocol (Gemcitabine and Docetaxel) -- 6.2.1.3 MVAC Protocol (Methotrexate, Vinblastine, Doxorubicin, and Cisplatin) -- 6.3 Pathophysiology of Prostate Cancer -- 6.3.1 Chemotherapy for the Treatment of Prostate Cancer."]
[{"$nulls":4},"6.4 Testicular Cancer -- 6.4.1 Chemotherapy for the Treatment of Testicular Cancer -- 6.4.1.1 BEP Protocol (Bleomycin, Etoposide, and Cisplatin) -- 6.4.1.2 VIP Protocol (Etoposide, Cisplatin, Ifosfamide, and Mesna) -- 6.4.1.3 TAXGEM Protocol (Paclitaxel and Gemcitabine) -- 6.4.1.4 TIP Protocol (Paclitaxel, Cisplatin, Ifosfamide, and Mesna) -- 6.4.1.5 VEIP Protocol (Vinblastine, Cisplatin, Ifosfamide, and Mesna) -- 6.5 Pathophysiology of Kidney Cancer -- 6.5.1 Chemotherapy for the Treatment of Kidney Cancer -- 6.5.1.1 PEMAX Protocol (Pembrolizumab and Axitinib) -- 6.5.1.2 Avelumab and Axitinib Protocol -- References -- Chapter 7: Chemotherapeutic Protocols for the Treatment of Gynecological Cancer -- 7.1 Epidemiological Profile of Gynecological Cancers -- 7.2 Pathophysiology of Ovarian Cancer -- 7.2.1 Chemotherapy for the Treatment of Epithelial Ovarian Cancer -- 7.2.1.1 CABR Protocol (Carboplatin and Abraxane) -- 7.2.1.2 CAPBEV Protocol (Carboplatin, Paclitaxel, and Bevacizumab) -- 7.2.1.3 CISP Protocol (Cisplatin and Paclitaxel) -- 7.2.1.4 CISPBEV Protocol (Cisplatin, Paclitaxel, and Bevacizumab) -- 7.2.1.5 CAD Protocol (Carboplatin and Docetaxel) -- 7.2.1.6 CAG Protocol (Carboplatin and Gemcitabine) -- 7.2.1.7 PLDC Protocol (Pegylated Liposomal Doxorubicin and Carboplatin) -- 7.2.1.8 BEVG Protocol (Bevacizumab and Gemcitabine) -- 7.2.1.9 BEVPLD Protocol (Bevacizumab and Pegylated Liposomal Doxorubicin) -- 7.2.1.10 BEVP Protocol (Bevacizumab and Paclitaxel) -- 7.2.2 Chemotherapy for the Treatment of Non-epithelial Ovarian Cancer -- 7.3 Pathophysiology of Cervical Cancer -- 7.3.1 Chemotherapy for the Treatment of Cervical Cancer -- "]
[{"$nulls":4},"7.4 Pathophysiology of Endometrial Cancer -- 7.4.1 Chemotherapy for the Treatment of Endometrial Cancer -- 7.5 Pathophysiology of Gestational Trophoblastic Neoplasia."]
[{"$nulls":4},"7.5.1 Chemotherapy for the Treatment of Gestational Trophoblastic Neoplasia."]
[null,"2.","Record Nr.",null,"UNISA996495567803316"]
[null,null,"Titolo",null,"Automated technology for verification and analysis : 20th International Symposium, ATVA 2022, Beijing, China, October 25-28, 2022, proceedings / / edited by Ahmed Bouajjani, Lukás Holík, and Zhilin Wu"]
[null,null,"Pubbl/distr/stampa",null,"Cham, Switzerland : , : Springer, , [2022]"]
[{"$nulls":4},"©2022"]
[null,null,"ISBN",null,"3-031-19992-8"]
[null,null,"Descrizione fisica",null,"1 online resource (442 pages)"]
[null,null,"Collana",null,"Lecture Notes in Computer Science ; ; v.13505"]
[null,null,"Disciplina",null,"511.3"]
[null,null,"Soggetti",null,"Automatic theorem proving"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Intro -- Preface -- Organization -- Abstracts of Invited Talks -- Compositional Reasoning about Concurrent Randomized Programs (Extended Abstract) -- Flattening String Constraints -- Runtime Assurance for Verified AI-Based Autonomy -- The Civl Verifier -- Subgame Perfect Equilibrium with an Algorithmic Perspective -- Contents -- Invited Paper -- Learning Monitorable Operational Design Domains for Assured Autonomy -- 1 Introduction -- 2 Motivating Example: Autonomous Lane Keeping -- 3 Optimal Monitors for Operational Design Domains -- 3.1 Learning Monitors for ODDs -- 3.2 Challenges in Learning Monitorable ODDs -- 3.3 Quantitative Monitor Learning -- 3.4 Black-Box vs. White-Box Settings -- 4 Framework -- 4.1 Main Workflow -- 4.2 Simulation-Based Analysis Using VerifAI and Scenic -- 4.3 Data Generation -- 4.4 Conformance Testing -- 5 Experiments -- 5.1 Experimental Setup -- 5.2 Results -- 6 Related Work -- 7 Conclusion -- References -- Reinforcement Learning -- Dynamic Shielding for Reinforcement Learning in Black-Box Environments -- 1 Introduction -- 1.1 Related Works -- 2 Preliminaries -- 2.1 Automata and Games for System Modeling -- 2.2 Safety Automata for Specifications -- 2.3 Shielding for Safe Reinforcement Learning -- 2.4 The RPNI Algorithm for Passive Automata Learning -- 3 Dynamic Shielding with Online Automata Inference -- 3.1 Dynamic Shielding Scheme -- 3.2 Challenge 1: Incompleteness of the Learned FSRS -- 3.3 Challenge 2: Precision in Automata Learning -- 3.4 Theoretical Validity of Our Dynamic Shielding -- 4 Experimental Evaluation -- 4.1 Implementation and Experiments -- 4.2 Benchmarks "]
[{"$nulls":4},"-- 4.3 RQ1: Safety by Dynamic Shielding in the Training Phase -- 4.4 RQ2: Performance of the Resulting Controller -- 4.5 RQ3: Time Efficiency of Dynamic Shielding -- 5 Conclusions and Perspectives -- References."]
[{"$nulls":4},"An Impossibility Result in Automata-Theoretic Reinforcement Learning -- 1 Introduction -- 2 Omega-Automata -- 3 Closure Properties of Acceptance Conditions -- 4 Markov Decision Processes -- 4.1 Optimal Strategies Against Omega-Automata -- 4.2 Optimal Strategies Against Scalar Rewards -- 5 Memoryless Reward Translations for RL -- 5.1 Memoryless Reward Translation -- 5.2 Conditions for Memoryless Reductions -- 6 Conclusion -- References -- Reusable Contracts for Safe Integration of Reinforcement Learning in Hybrid Systems -- 1 Introduction -- 2 Preliminaries -- 2.1 Reinforcement Learning -- 2.2 Simulink and the RL Toolbox -- 2.3 Deductive Verification with the Differential Dynamic Logic -- 2.4 Transformation from Simulink to dL -- 3 Related Work -- 4 Reusable Hybrid Contracts -- 4.1 Illustrating Examples -- 4.2 Recurring Elements -- 4.3 Threshold Pattern -- 4.4 Range Pattern -- 4.5 Range Recovery Pattern -- 4.6 Resilience Contracts -- 4.7 Deductive Verification in KeYmaera X -- 5 Conclusion -- References -- Program Analysis and Verification -- SISL: Concolic Testing of Structured Binary Input Formats via Partial Specification -- 1 Introduction -- 2 Scheme-Based Input Specification Language -- 3 Overview and Implementation -- 4 Experiments and Conclusion -- References -- Fence Synthesis Under the C11 Memory Model -- 1 Introduction -- 2 Overview of FenSying and fFenSying -- 3 Preliminaries -- 4 Background: C11 Memory Model -- 5 Invalidating Buggy Traces with C11 Fences -- 6 Methodology -- 7 Implementation and Results -- 8 Related Work -- 9 Conclusion and Future Work -- References -- Checking Scheduling-Induced Violations of Control Safety Properties -- 1 Introduction -- 2 System Model and Encoding -- 2.1 Control System Model and Evolution -- 2.2 Task Specification -- 2.3 An Abstraction for Task Runs -- 2.4 Control Action Update Modeling."]
[{"$nulls":4},"2.5 Composing Control and Scheduling Models -- 3 Refining the Abstraction -- 3.1 Overlapping Jobs -- 3.2 Schedule Violation -- 3.3 Work Conservation Violation -- 3.4 Unconstrained Control Updates -- 3.5 Correctness of Refinement -- 4 Tool Design -- 5 Case Study 1: DC Motor Control Model -- 6 Case Study 2: RC Network Control Model -- 7 Case Study 3: F1Tenth Car Model -- 8 Conclusions and Future Work -- References -- Symbolic Runtime Verification for Monitoring Under Uncertainties and Assumptions -- 1 Introduction -- 2 Preliminaries -- 3 A Framework for Symbolic Runtime Verification -- 3.1 Symbolic Expressions -- 3.2 Symbolic Monitor Semantics -- 3.3 A Symbolic Runtime Verification Algorithm -- 4 Symbolic Runtime Verification at Work -- 4.1 Application to Lola Fragments -- 4.2 Temporal Assumptions -- 5 Implementation and Empirical Evaluation -- 6 Conclusion -- References -- SMT and Verification -- Handling Polynomial and Transcendental Functions in SMT via Unconstrained Optimisation and Topological Degree Test -- 1 Introduction -- 2 Background -- 2.1 Unconstrained Global Optimisation -- 2.2 Interval Arithmetic -- 2.3 Robustness and Quasi-decidability -- 2.4 Topological Degree Test -- 3 Local Search Using Unconstrained Global Optimisation -- 4 Solving Bounded Instances with the Topological Degree Test and Interval Arithmetic -- 4.1 Quasi-decidability Procedure -- 4.2 From a Formula with nm to Quasi-dec -- 4.3 A General Procedure -- 5 From Constraint Sets to Formulas -- 5.1 An Eager Approach -- 5.2 A Lazy Approach -- 6 Experimental Evaluation -- 7 Conclusions and Future Work -- References -- Verification of SMT Systems with Quantifiers -- "]
[{"$nulls":4},"1 Introduction -- 2 Preliminaries -- 3 Verification of Quantified SMT Systems -- 3.1 Symbolic Formalism -- 3.2 Overview -- 3.3 Ground Instances -- 3.4 Generalizing Invariants from Instances -- 3.5 Invariant Checking."]
[{"$nulls":4},"3.6 Termination -- 4 Related Work -- 5 Experimental Evaluation -- 6 Conclusions and Future Work -- References -- Projected Model Counting: Beyond Independent Support -- 1 Introduction -- 2 Notation and Preliminaries -- 3 Related Work -- 4 Technical Contribution -- 4.1 Extremal Properties of GIS and UBS -- 4.2 Algorithm to Compute Projected Count Using UBS -- 5 Experimental Evaluation -- 6 Conclusion -- References -- Automata and Applications -- Minimization of Automata for Liveness Languages -- 1 Introduction -- 2 Preliminaries -- 2.1 Automata -- 2.2 Liveness Languages -- 2.3 Graphs, Nice Graphs, and the Vertex-Cover Problem -- 3 Live1 Languages -- 3.1 Minimizing Automata for Live1 and Doom1 Languages -- 4 Live2 Languages -- 4.1 Minimizing DBWs and GFG-NBWs for Live2 Languages -- 4.2 Minimizing DCWs and GFG-NCWs for Doom2 Languages -- 4.3 Minimizing Automata with Transition-Based Acceptance for Live2 Languages -- 5 Live3 Languages -- References -- Temporal Causality in Reactive Systems -- 1 Introduction -- 2 Preliminaries -- 3 Motivating Example -- 4 Property Causality -- 4.1 Interventions -- 4.2 Contingencies -- 4.3 Actual Causality for Trace Properties -- 5 Checking -Regular Causality -- 5.1 Interventions -- 5.2 Contingencies -- 5.3 Minimality -- 5.4 Deciding -Regular Causality -- 6 Related Work -- 7 Conclusion -- References -- PDAAAL: A Library for Reachability Analysis of Weighted Pushdown Systems -- 1 Introduction -- 2 Weighted Pushdown Systems and Reachability -- 3 Implemented Algorithms and PDAAAL Architecture -- 4 Comparison with State-of-the-Art -- 5 Applications -- 6 Conclusion -- References -- Active Learning -- Learning Deterministic One-Clock Timed Automata via Mutation Testing -- 1 Introduction -- 2 Preliminaries -- 2.1 Deterministic One-Clock Timed Automata -- 2.2 Active Learning Algorithm for DOTAs -- 2.3 Model-Based Mutation Testing."]
[{"$nulls":4},"3 Mutation-Based Testing for DOTAs -- 3.1 The Process Overview -- 3.2 Heuristic Test-Case Generation -- 3.3 Mutation and Score-Based Test-Case Selection -- 4 Learning-Friendly Mutation Operators for DOTAs -- 4.1 Timed Mutation Operator -- 4.2 Split-Location Mutation Operator -- 5 Implementation and Experiments -- 5.1 Case Studies -- 5.2 Evaluation of Improvements -- 6 Conclusion -- References -- Active Learning of One-Clock Timed Automata Using Constraint Solving -- 1 Introduction -- 2 Preliminaries -- 3 Learning Algorithm -- 3.1 Alignment and Comparison of Timed Words -- 3.2 Timed Observation Table -- 3.3 Encoding of Readiness Constraints -- 3.4 Hypothesis Construction -- 3.5 Main Algorithm and Correctness -- 4 Extension to Deterministic Timed Mealy Machines -- 5 Implementation and Experiments -- 5.1 Experiments on DOTAs -- 5.2 Experiments on TMMs -- 6 Conclusion -- References -- Learning and Characterizing Fully-Ordered Lattice Automata -- 1 Introduction -- 2 Preliminaries -- 3 A Myhill-Nerode Characterization for FOLAs -- 3.1 No Unique Minimal FOLA -- 3.2 Difficulties in Defining f -- 3.3 Defining the Equivalence Relation -- 3.4 The Correspondence Between f and a Minimal FOLA -- 4 The Learning Algorithm -- 5 Empirical Results -- 6 Conclusions -- References -- Probabilistic and Stochastic Systems -- Optimistic and Topological Value Iteration for Simple Stochastic Games -- 1 Introduction -- 2 Preliminaries -- 2.1 Simple Stochastic Games -- 2.2 Value Iteration and Bounded Value Iteration -- 3 Optimistic Value Iteration -- 4 Precise Topological Value Iteration -- 5 Random Generation of Simple Stochastic Games -- 6 Experiments -- 6.1 "]
[{"$nulls":4},"Experimental Setup -- 6.2 Overview -- 6.3 Detailed Analysis of Precise Algorithms -- 6.4 Detailed Analysis of Approximate (-Precise) Algorithms -- 7 Conclusion -- References -- Alternating Good-for-MDPs Automata."]
[{"$nulls":4},"1 Introduction."]